Samra Turajlic
Overview
Explore the profile of Samra Turajlic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
7865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernandez-Sanroman A, Fendler A, Tan B, Cattin A, Spencer C, Thompson R, et al.
Cancer Discov
. 2025 Jan;
OF1-OF23.
PMID: 39784160
Using joint genomic-transcriptomic analysis of 243 samples, we reveal recurrent patterns of nongenetic evolution in ccRCC not exclusively governed by genetic factors, including T-cell depletion, tumor T-cell receptor coevolution, potential...
2.
Fernandez-Sanroman A, Fendler A, Tan B, Cattin A, Spencer C, Thompson R, et al.
Cancer Discov
. 2025 Jan;
PMID: 39774619
While the key aspects of genetic evolution and their clinical implications in clear cell renal-cell carcinoma (ccRCC) are well-documented, how genetic features co-evolve with the phenotype and tumor microenvironment (TME)...
3.
Devito L, Lim E, OToole S, Shepherd S, Deng D, Feng H, et al.
Stem Cell Res
. 2024 Nov;
81:103611.
PMID: 39549334
VHL disease is an inherited and autosomal dominant disorder affecting 1 in 36,0000 individuals worldwide. It is caused by von Hippel-Lindau (VHL) gene mutations and can affect both genders and...
4.
Marandino L, Campi R, Amparore D, Tippu Z, Albiges L, Capitanio U, et al.
Eur Urol Oncol
. 2024 Sep;
PMID: 39327187
Context: Immune-oncology strategies are revolutionising the perioperative treatment in several tumour types. The perioperative setting of renal cell carcinoma (RCC) is an evolving field, and the advent of immunotherapy is...
5.
Culliford R, Lawrence S, Mills C, Tippu Z, Chubb D, Cornish A, et al.
Nat Commun
. 2024 Jul;
15(1):5935.
PMID: 39009593
Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer, but a comprehensive description of its genomic landscape is lacking. We report the whole genome sequencing...
6.
Buckley M, Terwagne C, Ganner A, Cubitt L, Brewer R, Kim D, et al.
Nat Genet
. 2024 Jul;
56(7):1446-1455.
PMID: 38969834
To maximize the impact of precision medicine approaches, it is critical to identify genetic variants underlying disease and to accurately quantify their functional effects. A gene exemplifying the challenge of...
7.
Widman A, Shah M, Frydendahl A, Halmos D, Khamnei C, Ogaard N, et al.
Nat Med
. 2024 Jun;
30(6):1655-1666.
PMID: 38877116
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of...
8.
Yiu D, Aguilar-Duran S, Edwards C, Chauhan D, Furness A, Turajlic S, et al.
Br J Dermatol
. 2024 May;
191(3):465-467.
PMID: 38753744
No abstract available.
9.
Gudd C, Mitchell E, Atkinson S, Mawhin M, Turajlic S, Larkin J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38580334
Background: Checkpoint inhibitor-induced hepatitis (CPI-hepatitis) is an emerging problem with the widening use of CPIs in cancer immunotherapy. Here, we developed a mouse model to characterize the mechanism of CPI-hepatitis...
10.
Larkin J, Marais R, Porta N, Gonzalez de Castro D, Parsons L, Messiou C, et al.
Cell Rep Med
. 2024 Feb;
5(3):101435.
PMID: 38417447
Mucosal (MM) and acral melanomas (AM) are rare melanoma subtypes of unmet clinical need; 15%-20% harbor KIT mutations potentially targeted by small-molecule inhibitors, but none yet approved in melanoma. This...